NAD (NAD+)

If you have been hearing about NAD+ from longevity podcasts, supplement marketing, or clinic IV drips, this test is how you find out what your actual level looks like instead of guessing. NAD+ (nicotinamide adenine dinucleotide) sits at the center of how your cells make energy and repair damage, and animal research has consistently linked low levels to many of the problems we associate with getting older.

This is still a research-grade measurement, not a settled clinical test. There are no agreed-on cutoffs and no major guideline tells you what your number should be. What it gives you is a baseline you can track over time, especially if you are taking NAD precursor supplements or making lifestyle changes designed to support cellular energy.

What This Test Actually Measures

This test quantifies NAD+ in whole blood. NAD+ exists inside every cell as part of a pair with its reduced form, NADH, and the balance between the two reflects how busy your cells are turning food into energy. NAD+ also gets used up by enzymes that repair DNA, control which genes are active, and respond to inflammation.

Two things are worth knowing up front. First, the amount of NAD+ in your blood is roughly 500 times lower than the amount inside your cells, where the action actually happens. Blood is a proxy, not a direct readout of what your tissues are doing. Second, NAD+ inside your cells turns over rapidly, with a measured half-life on the order of an hour in the cytoplasm and nucleus (and roughly eight hours in mitochondria), which is why a single snapshot tells you less than a pattern of measurements over time.

Why Levels Change With Age

In a community study of more than 1,500 adults, average whole blood NAD+ levels were higher in men than in women, and men aged 60 and older had measurably lower NAD+ than men under 30. In women, levels stayed relatively flat across age groups.

A separate analysis of human skin tissue found that NAD+ declined with age in both sexes, with the link being stronger in men than in women. The pattern is consistent across studies: NAD+ availability tends to fall as you age, and the decline appears to start earlier and run deeper in men.

Metabolic Health and the Counterintuitive Finding

Here is where the picture gets more complicated. In a community study, people in the highest quartile of whole blood NAD+ were about three times as likely to have metabolic disease as people in the lowest quartile (adjusted odds ratio 3.01, 95% CI 1.87 to 4.87). Risk started rising at higher NAD+ levels.

That finding cuts against the simple story that more NAD+ is always better. The most likely explanation is that whole blood NAD+ is not a clean good-number versus bad-number marker. It can rise because cells are healthier, or it can rise because metabolic stress is changing how the molecule is being made and used. This is one reason a single high or low reading does not translate directly into a diagnosis or a treatment plan.

Heart Failure

In a study of very old hospitalized adults with heart failure, average whole blood NAD+ was lower than in healthy blood donors (roughly 12% lower than the typical control reference). A separate analysis of patients with class II to III heart failure found whole blood NAD+ about 28% lower than in controls. These are observational findings, not proof that low NAD+ caused the heart failure, but they fit a broader pattern of low NAD+ tracking with serious cardiovascular illness.

Neurological Disease

In adults with demyelinating neurological disease (the category that includes multiple sclerosis), whole blood NAD+ was roughly 22% lower than in healthy controls. As with heart failure, the data are observational and cross-sectional. They tell you that low NAD+ shows up alongside the disease, not that raising NAD+ would treat it.

Inflammation

Levels of extracellular NAD+ in plasma tracked inversely with C-reactive protein (a marker of body-wide inflammation), with a moderate inverse link. Hemoglobin (the oxygen-carrying protein in red blood cells) tracked positively with NAD+ at a similar moderate strength. The takeaway is that systemic inflammation appears to drag NAD+ down.

Reconciling the Picture

You now have two findings that look like they contradict each other: low NAD+ shows up in serious disease, but very high NAD+ shows up alongside metabolic dysfunction in healthier people. The way to hold both together is to treat NAD+ as a marker of cellular activity rather than a thermometer for health. Both ends of the distribution can reflect something off-pattern. This is exactly the reason a single number is not enough, and why your own trend over time is more informative than any one reading.

Why One Reading Is Not Enough

NAD+ turnover is fast at the cellular level, and individual responses to interventions vary widely. In one supplementation trial, the variation in how much people's NAD+ moved ranged from 29% to 113%, meaning the same dose produced very different results in different people. At the same time, individual baselines have been shown to stay relatively stable over a 100-day window when nothing changes.

The practical move is to establish your own baseline before drawing conclusions. Get one reading, repeat it within a few weeks under similar conditions to confirm you have a real number rather than a noisy one, then retest in 3 to 6 months if you are starting a precursor supplement or a new training program. After that, at least once a year is reasonable if you want to watch the long-term trajectory.

What to Do With an Unexpected Result

Because there are no established cutoffs, the question is rarely whether your number crosses a threshold. It is whether your number fits a pattern. A reading that surprises you is worth retesting before you act on it, ideally first thing in the morning, well-hydrated, away from intense exercise the day before, and not in the middle of a viral illness.

If repeated readings are persistently low and you have other findings pointing toward metabolic dysfunction, cardiovascular issues, or chronic inflammation, the workup belongs with companion tests rather than another NAD+ measurement. Think about pairing it with hs-CRP (a sensitive inflammation marker), HbA1c (your three-month blood sugar average), a full lipid panel including ApoB, and markers of liver and kidney function. If you are pursuing NAD precursor therapy, your decision to continue, adjust, or stop should rest on the broader picture, not on NAD+ alone.

When Results Can Be Misleading

• Sample handling: prolonged centrifugation and faster braking during processing can artificially lower extracellular NAD+ readings. Because plasma NAD+ is hundreds of times lower than the NAD+ inside blood cells, even small amounts of cell damage during draw or spin can distort the number.
• Recent intense exercise: a single workout raises NAD+ inside circulating immune cells and lowers blood nicotinamide for hours afterward. A draw within 24 hours of a hard session can read differently than a baseline draw.
• Acute illness or inflammation: when CRP is elevated from a recent infection or flare, NAD+ tends to be lower at the same time. Wait until you are well before drawing.
• Method variation between labs: enzymatic cycling assays, mass spectrometry, and bioluminescent readouts can produce different absolute numbers for the same sample. If you are tracking a trend, use the same lab and the same method every time.